| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aee09a31143b85ebd99fe2e060cd9015 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20023 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5094
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
| filingDate |
2019-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d5c824d340dc4bebee4bc90e405fc68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_203d9ff7fb0f4299d5af087c9affa094
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d991134c51f3f46e5576869793fa4f0c |
| publicationDate |
2021-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113396155-A |
| titleOfInvention |
Conjugated virus-like particles and their use as antitumor immune redirectors |
| abstract |
The present invention discloses a new class of conjugated virus-like particles (VLPs). These conjugated VLPs bind to a wide variety of tumors and contain epitopes recognized by preexisting T cell immune responses in the host. These epitopes are derived from pathogens or previous vaccinations (such as early childhood vaccines). This motivates the body's pre-existing cytotoxic immunity, acquired through previous infection or previous childhood vaccination, to be redirected to tumor cells to eliminate cancer, and to develop long-term anti-tumor immunity. The conjugated VLPs can be used to modulate a wide range of tumors to be affected by responses from existing immunity, thereby circumventing the need to identify tumor antigens or generate tumor-specific immune responses. The compositions and methods broaden the opportunity to treat all cancer types in subjects previously suffering from untargetable cancers due to various technical and biological limitations of currently available immunotherapy drugs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110891602-A |
| priorityDate |
2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |